Clinical Specialties & Body Systems

Deep dives by specialty—organs, systems, and diseases managed by expert teams.

  • 16 Subtopics
  • 5 Tracked terms
  • Last 30 days Feed window

Inside Clinical Specialties & Body Systems

Cardiology & Metabolic Health Heart disease, hypertension, lipids, diabetes, and metabolic syndrome. Oncology & Hematology Cancer prevention, screening, therapies, survivorship, and blood disorders. Neurology & Neuroscience Stroke, migraine, epilepsy, neurodegeneration, and movement disorders. Orthopedics & Sports Medicine Bones, joints, tendons; injuries, imaging, and surgical/rehab options. Respiratory & Pulmonology Asthma, COPD, sleep apnea, infections, and environmental lung risks. Gastroenterology & Hepatology Gut health, IBD/IBS, reflux, liver disease, and microbiome research. Endocrinology & Hormones Thyroid, adrenal, reproductive hormones, and metabolic disorders of glands. Nephrology & Urology Kidneys, dialysis, stones, infections, prostate, and continence concerns. Dermatology Skin cancer checks, eczema/psoriasis, acne care, and cosmetic dermatology news. Rheumatology & Autoimmune Arthritis, lupus, vasculitis, biologics, and immune‑modulating therapies. OB‑GYN (Women’s Health) Reproductive health, pregnancy, menopause, and gynecologic care advances. Pediatrics & Adolescent Health Well‑child care, vaccinations, development, and school health issues. Geriatrics & Healthy Aging Falls, cognition, polypharmacy, frailty, and independence strategies. Ophthalmology & Vision Glaucoma, cataracts, macular degeneration, and eye‑care technology updates. ENT (Ear, Nose & Throat) Hearing loss, sinus and allergy care, voice, and sleep‑related airway issues. Dentistry & Oral Health Preventive dentistry, periodontal disease, orthodontics, and oral surgery care.

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Clinical Specialties & Body Systems


seekingalpha.com > news > 4642676-johnson-and-johnson-contineum-depression-candidate-fails-phase-2

J&J/Contineum depression candidate fails in phase 2

10+ min ago   (18+ words) J&J’s JNJ-5120 (PIPE-307) missed its phase 2 MOONLIGHT-1 primary endpoint in major depressive disorder. Read more here....


usatoday.com > story > money > money-management > healthcare > 09/14/2026 > ai-medical-innovation-healthcare > 91713919007

AI innovation is reshaping healthcare from diagnosis to drug discovery

8+ hour, 50+ min ago   (486+ words) In science fiction, futuristic medical technology often appears in a doctor’s hand. Think of Dr. McCoy scanning a patient using a tricorder wand in Star Trek. These innovations are making diagnosis faster. But can they make it better? Early evidence…...


wsau.com > 09/14/2026 > contineum-jjs-depression-drug-fails-to-meet-mid-stage-trial-goal

Contineum, J&J’s depression drug fails to meet mid-stage trial goal

21+ min ago   (209+ words) Sept 15 (Reuters) – Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet ​the main goal of a mid-stage ‌study. • The trial was testing the drug, JNJ-5120 or PIPE-307, in patients with major depressive disorder,…...


thebrighterside.news > post > tiny-spinning-probe-brings-360-degree-view-inside-arteries

Tiny spinning probe brings 360-degree view inside arteries

52+ min ago   (1015+ words) A 0.55-mm optical probe imaged stents and plaque while reducing rotational distortion inside curved cerebral vessels. (CREDIT: Dawei Wu, Nanjing University of Aeronautics and Astronautics) A probe barely wider than half a millimeter has navigated a model of the human…...


medcitynews.com > 2026 > 09 > scholar-rock-drug-wins-first-in-class-approval-in-rare-neuromuscular-disease

Scholar Rock Drug Wins First-in-Class Approval in Rare Neuromuscular Disease

1+ hour, 32+ min ago   (308+ words) Scholar Rock’s Isembyld isn’t the only FDA-approved therapy for spinal muscular atrophy, but it is the first one that directly targets muscle tissue. Isembyld is the first commercial product for Scholar Rock, which is also evaluating the antibody in other…...


postandcourier.com > moultrie-news > news > leaders-advocate-for-health-and-fighting-heart-disease > article_2725b574-746a-437a-9b21-424660278e16.html

Fantastic Four: Leaders advocate for health and fighting heart disease

1+ hour, 59+ min ago   (318+ words) Four Charleston-area leaders are joining the American Heart Association’s Leaders of Impact™ campaign, a seven-week initiative to raise awareness and funds to prevent cardiovascular disease, the leading cause of death nationwide. More than 61 percent of the US population is expected…...


medicaldialogues.in > pulmonology > news > vtd-shows-potential-to-modify-cystic-fibrosis-progression-in-young-children-study-179213

VTD Shows Potential to Modify Cystic Fibrosis Progression in Young Children: Study

5+ hour, 14+ min ago   (54+ words) Ten Years to Dapagliflozin Metformin FDC Approval in India - 10 Key Points to Revisit Overcoming the Challenge of Maintaining Weight Reduction Sympathetic Overactivity: The Driver of Hypertension in Young Indians India's Medical Startups: From Innovation to Impact - Prof. (Dr) Yogendra Kumar…...


markets.businessinsider.com > news > stocks > santa-ana-bio-announces-first-subjects-dosed-in-phase-1-study-of-sab01-to-treat-autoimmune-inflammatory-diseases-1036542739

Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases

19+ hour, 50+ min ago   (402+ words) First-in-class bispecific antibody designed for mast cell elimination without the safety issues associated with current KIT therapeuticsPhase 1 si... Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases - First-in-class bispecific antibody designed for mast…...